Core Viewpoint - The law firm Kirby McInerney LLP is investigating Hub Group, Inc. for potential violations of federal securities laws and other unlawful business practices by the company and/or its senior management [1] Group 1 - Hub Group disclosed on January 5, 2026, that it had identified an error leading to the understatement of purchased [1]

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. and its executives due to significant stock price drops linked to potential violations of federal securities laws [1][3]. Group 1: Company Overview - Fermi Inc. is an energy and AI infrastructure company aiming to build large-scale nuclear reactors to support a network of grid-independent data centers for AI companies [4]. - The company's flagship project, Project Matador, is designed to provide dedicated power for AI workloads [4]. Group 2: IPO and Allegations - Fermi completed its IPO in October 2025, claiming strong demand for Project Matador and securing a 20-year lease with an investment-grade-rated tenant [5]. - Allegations suggest that Fermi overstated tenant demand and misrepresented the agreement with the First Tenant [6]. Group 3: Stock Performance and Impact - On December 12, 2025, Fermi's stock dropped by $5.16 per share, over 33%, following the announcement that the First Tenant was terminating the Advance in Aid of Construction Agreement [7]. - The stock price fell from $15.25 per share on December 11, 2025, to $10.09 per share on December 12, 2025, reflecting investor concerns over the company's disclosures [7].

Core Viewpoint - Wealthfront Corporation is under investigation for potential violations of federal securities laws, particularly concerning misleading statements made during its IPO process [1][3]. Group 1: Company Overview - Wealthfront is an online financial advisor that utilizes automated tools to provide investment and financial advice [2]. - The company completed its initial public offering (IPO) on December 12, 2025, offering over 34 million shares at a price of $14.00 per share [2]. Group 2: Financial Performance - Wealthfront reported net deposit outflows of $208 million for its first quarterly results as a publicly traded company, a significant decline from the $874 million in inflows during the same period the previous year [4]. - The stock price of Wealthfront dropped by $2.12 per share, nearly 17%, from $12.59 on January 12, 2026, to $10.47 on January 13, 2026, following the release of these results [4]. Group 3: Management Insights - CEO David Fortunato attributed the decline in deposits to falling interest rates and highlighted the strategic importance of Wealthfront's new home-lending business as a protective measure against further declines [4]. - Fortunato disclosed that he holds a 95.1% stake in Wealthfront's home-lending business and mentioned the possibility of revisiting the ownership structure [4].

Core Viewpoint - The law firm Kirby McInerney LLP is investigating Camping World Holdings, Inc. for potential violations of federal securities laws and other unlawful business practices by the company or its senior management [1] Group 1 - On October 28, 2025, Camping World announced its third-quarter 2025 financial results [1]

Core Viewpoint - The law firm Kirby McInerney LLP is investigating Lakeland Industries, Inc. for potential violations of federal securities laws and other unlawful business practices by the company and/or its senior management [1] Group 1 - Lakeland Industries reported third quarter earnings on December 9, 2025, with net sales of $47.6 million [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by November 18, 2025 [1][3]. Company Overview - Jasper Therapeutics, Inc. is facing scrutiny for allegedly lacking necessary controls and procedures for third-party manufacturers, which may have impacted the integrity of clinical trials and the prospects of its products, particularly briquilimab [3]. Legal Allegations - The complaint against Jasper claims that the company made false or misleading statements regarding its manufacturing processes and the viability of its clinical trials, which could lead to overstated business and financial prospects [3]. - Specific allegations include the failure to ensure compliance with current Good Manufacturing Practices (cGMP), which increased the risk of confounded study results and potential cost-reduction measures [3]. Recent Developments - On July 7, 2025, Jasper reported issues with a drug product lot used in clinical trials, leading to a significant drop in stock price by $3.73 per share, or 55.1%, closing at $3.04 per share [4]. - The company announced a halt in the ETESIAN Study and paused development in asthma and SCID, contradicting previous statements about its financial stability and cash runway [4]. Investor Actions - Investors who suffered losses between November 30, 2023, and July 3, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][6]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Jasper's conduct [6].